Soleno Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
203 Redwood Shores Pkwy Ste 500, Redwood...Phone Number
(650) 213-8444Website
soleno.lifeRevenue
$285 MillionStock Symbol
SLNOIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Soleno Therapeutics
Soleno Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics aimed at treating rare genetic disorders. The company's lead candidate, DCCR (Diazoxide Choline) Extended-Release tablets, is under evaluation for the treatment of Prader-Willi syndrome (PWS). Soleno's mission is to create effective therapeutic options for patients with complex and life-threatening rare diseases that currently lack treatment. Their primary focus includes advancing research that positively impacts the lives of patients and their families.Explore more
Soleno Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Soleno Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Soleno Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Soleno Therapeutics
Check if Soleno Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Soleno Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Soleno Therapeutics recently announced quarterly report
Soleno Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Soleno Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Check out if Soleno Therapeutics is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Soleno Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Soleno Therapeutics
Compare insights from companies similar to Soleno Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$105M
201-500
Public
$237.2M
1997
CE
Celia EckertSenior Vice President, General Counsel & Corporate Secretary
Company Profile Activity
Activity Insights
Soleno Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Soleno Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Soleno Therapeutics.
Soleno Therapeutics financials insights
Gather financial insights about Soleno Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Other Financing Round
$60M
Soleno Therapeutics Tech Stack
A closer look at the technologies used by Soleno Therapeutics
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Open Position
Open Position
Soleno Therapeutics News & Media
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
Strengthens Neurocrine's rare disease portfolio with VYKAT⢠XR, the first and only approved treatment for hyperphagia in Prader-Willi syndrome Adds recently launched therapy with strong early adoption and meaningful commercial potential SAN DIEGO, May 18, 2026 /PRNewswire/ -- Neurocrine...SLNO 8-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Securities Class Action Alleging Hyperphagia Drug Launch Disruptions - Hagens Berman
SAN FRANCISCO, May 11, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class action and the upcoming May 5, 2026 lead plaintiff deadline. The firm urges investors who purchased...SLNO DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Today's Lead Plaintiff Deadline in Securities Class Action
SAN FRANCISCO, May 5, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class action and the upcoming May 5, 2026 lead plaintiff deadline. The firm urges investors who purchased...SLNO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Soleno Therapeutics
Sign Up For FreeTo access detailed company insights
Soleno Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics aimed at treating rare genetic disorders. The company's lead candidate, DCCR (Diazoxide Choline) Extended-Release tablets, is under evaluation for the treatment of Prader-Willi syndrome (PWS). Soleno's mission is to... Read More
